Nova Cannabis Inc.
Nova Cannabis Inc. (NVACF) Stock Competitors & Peer Comparison
See (NVACF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVACF | $1.26 | -2.77% | 78.5M | 31.60 | $0.04 | N/A |
| ALBHF | $0.62 | +0.00% | 10B | 62.00 | $0.01 | N/A |
| ALBBY | $12.15 | +0.00% | 9.8B | 48.60 | $0.25 | N/A |
| MSMKF | $21.20 | +0.00% | 8.4B | 23.30 | $0.91 | +1.42% |
| DCHPF | $46.90 | -0.21% | 5.3B | -151.29 | -$0.31 | N/A |
| CLCGY | $42.14 | +1.29% | 5B | 29.68 | $1.42 | +0.54% |
| RGEDF | $27.17 | +0.00% | 5B | 7.99 | $3.40 | +4.93% |
| GEDSF | $24.85 | -0.00% | 4.5B | 10.71 | $2.32 | +5.89% |
| RADLY | $2.52 | -6.67% | 4.3B | 19.24 | $0.13 | +2.21% |
| CSMYF | $46.06 | +0.00% | 3.7B | 19.77 | $2.33 | +1.03% |
Stock Comparison
NVACF vs ALBHF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ALBHF has a market cap of 10B. Regarding current trading prices, NVACF is priced at $1.26, while ALBHF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ALBHF's P/E ratio is 62.00. In terms of profitability, NVACF's ROE is +0.02%, compared to ALBHF's ROE of +0.06%. Regarding short-term risk, NVACF is more volatile compared to ALBHF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check ALBHF's competition here
NVACF vs ALBBY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ALBBY has a market cap of 9.8B. Regarding current trading prices, NVACF is priced at $1.26, while ALBBY trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ALBBY's P/E ratio is 48.60. In terms of profitability, NVACF's ROE is +0.02%, compared to ALBBY's ROE of +0.06%. Regarding short-term risk, NVACF is more volatile compared to ALBBY. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check ALBBY's competition here
NVACF vs MSMKF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, MSMKF has a market cap of 8.4B. Regarding current trading prices, NVACF is priced at $1.26, while MSMKF trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas MSMKF's P/E ratio is 23.30. In terms of profitability, NVACF's ROE is +0.02%, compared to MSMKF's ROE of +0.11%. Regarding short-term risk, NVACF is less volatile compared to MSMKF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check MSMKF's competition here
NVACF vs DCHPF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, DCHPF has a market cap of 5.3B. Regarding current trading prices, NVACF is priced at $1.26, while DCHPF trades at $46.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas DCHPF's P/E ratio is -151.29. In terms of profitability, NVACF's ROE is +0.02%, compared to DCHPF's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to DCHPF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check DCHPF's competition here
NVACF vs CLCGY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, CLCGY has a market cap of 5B. Regarding current trading prices, NVACF is priced at $1.26, while CLCGY trades at $42.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas CLCGY's P/E ratio is 29.68. In terms of profitability, NVACF's ROE is +0.02%, compared to CLCGY's ROE of +0.49%. Regarding short-term risk, NVACF is more volatile compared to CLCGY. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check CLCGY's competition here
NVACF vs RGEDF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, RGEDF has a market cap of 5B. Regarding current trading prices, NVACF is priced at $1.26, while RGEDF trades at $27.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas RGEDF's P/E ratio is 7.99. In terms of profitability, NVACF's ROE is +0.02%, compared to RGEDF's ROE of +0.20%. Regarding short-term risk, NVACF is less volatile compared to RGEDF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check RGEDF's competition here
NVACF vs GEDSF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, GEDSF has a market cap of 4.5B. Regarding current trading prices, NVACF is priced at $1.26, while GEDSF trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas GEDSF's P/E ratio is 10.71. In terms of profitability, NVACF's ROE is +0.02%, compared to GEDSF's ROE of +0.19%. Regarding short-term risk, NVACF is more volatile compared to GEDSF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check GEDSF's competition here
NVACF vs RADLY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, RADLY has a market cap of 4.3B. Regarding current trading prices, NVACF is priced at $1.26, while RADLY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas RADLY's P/E ratio is 19.24. In terms of profitability, NVACF's ROE is +0.02%, compared to RADLY's ROE of +0.18%. Regarding short-term risk, NVACF is more volatile compared to RADLY. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check RADLY's competition here
NVACF vs CSMYF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, CSMYF has a market cap of 3.7B. Regarding current trading prices, NVACF is priced at $1.26, while CSMYF trades at $46.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas CSMYF's P/E ratio is 19.77. In terms of profitability, NVACF's ROE is +0.02%, compared to CSMYF's ROE of +0.08%. Regarding short-term risk, NVACF is more volatile compared to CSMYF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check CSMYF's competition here
NVACF vs WLCGF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, WLCGF has a market cap of 3.4B. Regarding current trading prices, NVACF is priced at $1.26, while WLCGF trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas WLCGF's P/E ratio is 19.54. In terms of profitability, NVACF's ROE is +0.02%, compared to WLCGF's ROE of +0.06%. Regarding short-term risk, NVACF is more volatile compared to WLCGF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check WLCGF's competition here
NVACF vs SDGCF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SDGCF has a market cap of 3.3B. Regarding current trading prices, NVACF is priced at $1.26, while SDGCF trades at $28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SDGCF's P/E ratio is 17.40. In terms of profitability, NVACF's ROE is +0.02%, compared to SDGCF's ROE of +0.12%. Regarding short-term risk, NVACF is more volatile compared to SDGCF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check SDGCF's competition here
NVACF vs SHPPF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SHPPF has a market cap of 3B. Regarding current trading prices, NVACF is priced at $1.26, while SHPPF trades at $148.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SHPPF's P/E ratio is -52.01. In terms of profitability, NVACF's ROE is +0.02%, compared to SHPPF's ROE of -0.10%. Regarding short-term risk, NVACF is less volatile compared to SHPPF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check SHPPF's competition here
NVACF vs SGIPF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SGIPF has a market cap of 2.9B. Regarding current trading prices, NVACF is priced at $1.26, while SGIPF trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SGIPF's P/E ratio is 20.11. In terms of profitability, NVACF's ROE is +0.02%, compared to SGIPF's ROE of +0.11%. Regarding short-term risk, NVACF is less volatile compared to SGIPF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check SGIPF's competition here
NVACF vs TSUSF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, TSUSF has a market cap of 2.7B. Regarding current trading prices, NVACF is priced at $1.26, while TSUSF trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas TSUSF's P/E ratio is 16.87. In terms of profitability, NVACF's ROE is +0.02%, compared to TSUSF's ROE of +0.06%. Regarding short-term risk, NVACF is less volatile compared to TSUSF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check TSUSF's competition here
NVACF vs SAEYY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SAEYY has a market cap of 2.4B. Regarding current trading prices, NVACF is priced at $1.26, while SAEYY trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SAEYY's P/E ratio is -41.96. In terms of profitability, NVACF's ROE is +0.02%, compared to SAEYY's ROE of -0.10%. Regarding short-term risk, NVACF is more volatile compared to SAEYY. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check SAEYY's competition here
NVACF vs HTSUY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, HTSUY has a market cap of 2B. Regarding current trading prices, NVACF is priced at $1.26, while HTSUY trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas HTSUY's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to HTSUY's ROE of +0.08%. Regarding short-term risk, NVACF is less volatile compared to HTSUY. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check HTSUY's competition here
NVACF vs BJTRF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, BJTRF has a market cap of 542.8M. Regarding current trading prices, NVACF is priced at $1.26, while BJTRF trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas BJTRF's P/E ratio is 8.10. In terms of profitability, NVACF's ROE is +0.02%, compared to BJTRF's ROE of +0.03%. Regarding short-term risk, NVACF is more volatile compared to BJTRF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check BJTRF's competition here
NVACF vs ZRSEF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ZRSEF has a market cap of 508.5M. Regarding current trading prices, NVACF is priced at $1.26, while ZRSEF trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ZRSEF's P/E ratio is -2.14. In terms of profitability, NVACF's ROE is +0.02%, compared to ZRSEF's ROE of -0.26%. Regarding short-term risk, NVACF is less volatile compared to ZRSEF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check ZRSEF's competition here
NVACF vs HTPRF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, HTPRF has a market cap of 12.1M. Regarding current trading prices, NVACF is priced at $1.26, while HTPRF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas HTPRF's P/E ratio is -0.06. In terms of profitability, NVACF's ROE is +0.02%, compared to HTPRF's ROE of +0.11%. Regarding short-term risk, NVACF is more volatile compared to HTPRF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check HTPRF's competition here
NVACF vs PNPL Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, PNPL has a market cap of 10.2M. Regarding current trading prices, NVACF is priced at $1.26, while PNPL trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas PNPL's P/E ratio is -14.00. In terms of profitability, NVACF's ROE is +0.02%, compared to PNPL's ROE of +0.54%. Regarding short-term risk, NVACF is more volatile compared to PNPL. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check PNPL's competition here
NVACF vs ETBI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ETBI has a market cap of 9M. Regarding current trading prices, NVACF is priced at $1.26, while ETBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ETBI's P/E ratio is -0.40. In terms of profitability, NVACF's ROE is +0.02%, compared to ETBI's ROE of +0.00%. Regarding short-term risk, NVACF is less volatile compared to ETBI. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check ETBI's competition here
NVACF vs FFLWF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, FFLWF has a market cap of 5.4M. Regarding current trading prices, NVACF is priced at $1.26, while FFLWF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas FFLWF's P/E ratio is -0.08. In terms of profitability, NVACF's ROE is +0.02%, compared to FFLWF's ROE of -0.97%. Regarding short-term risk, NVACF is less volatile compared to FFLWF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check FFLWF's competition here
NVACF vs RLLVF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, RLLVF has a market cap of 5.3M. Regarding current trading prices, NVACF is priced at $1.26, while RLLVF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas RLLVF's P/E ratio is -0.60. In terms of profitability, NVACF's ROE is +0.02%, compared to RLLVF's ROE of +2.21%. Regarding short-term risk, NVACF is less volatile compared to RLLVF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check RLLVF's competition here
NVACF vs HEWA Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, HEWA has a market cap of 4.5M. Regarding current trading prices, NVACF is priced at $1.26, while HEWA trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas HEWA's P/E ratio is -3.50. In terms of profitability, NVACF's ROE is +0.02%, compared to HEWA's ROE of -0.02%. Regarding short-term risk, NVACF is more volatile compared to HEWA. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check HEWA's competition here
NVACF vs GABLF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, GABLF has a market cap of 2.7M. Regarding current trading prices, NVACF is priced at $1.26, while GABLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas GABLF's P/E ratio is -0.04. In terms of profitability, NVACF's ROE is +0.02%, compared to GABLF's ROE of +2.91%. Regarding short-term risk, NVACF is more volatile compared to GABLF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check GABLF's competition here
NVACF vs SYDRF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SYDRF has a market cap of 2.3M. Regarding current trading prices, NVACF is priced at $1.26, while SYDRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SYDRF's P/E ratio is 8.00. In terms of profitability, NVACF's ROE is +0.02%, compared to SYDRF's ROE of +0.96%. Regarding short-term risk, NVACF is less volatile compared to SYDRF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check SYDRF's competition here
NVACF vs IWINF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, IWINF has a market cap of 1.7M. Regarding current trading prices, NVACF is priced at $1.26, while IWINF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas IWINF's P/E ratio is -0.06. In terms of profitability, NVACF's ROE is +0.02%, compared to IWINF's ROE of -0.21%. Regarding short-term risk, NVACF is more volatile compared to IWINF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check IWINF's competition here
NVACF vs LGNZZ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, LGNZZ has a market cap of 1.4M. Regarding current trading prices, NVACF is priced at $1.26, while LGNZZ trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas LGNZZ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to LGNZZ's ROE of -0.16%. Regarding short-term risk, NVACF is more volatile compared to LGNZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check LGNZZ's competition here
NVACF vs NUTTQ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, NUTTQ has a market cap of 1.1M. Regarding current trading prices, NVACF is priced at $1.26, while NUTTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas NUTTQ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to NUTTQ's ROE of +3.01%. Regarding short-term risk, NVACF is less volatile compared to NUTTQ. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check NUTTQ's competition here
NVACF vs CNBI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, CNBI has a market cap of 686.8K. Regarding current trading prices, NVACF is priced at $1.26, while CNBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas CNBI's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to CNBI's ROE of +0.17%. Regarding short-term risk, NVACF is less volatile compared to CNBI. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check CNBI's competition here
NVACF vs RADCQ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, RADCQ has a market cap of 559.7K. Regarding current trading prices, NVACF is priced at $1.26, while RADCQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas RADCQ's P/E ratio is -0.00. In terms of profitability, NVACF's ROE is +0.02%, compared to RADCQ's ROE of +3.01%. Regarding short-term risk, NVACF is less volatile compared to RADCQ. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check RADCQ's competition here
NVACF vs LGNYZ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, LGNYZ has a market cap of 484.3K. Regarding current trading prices, NVACF is priced at $1.26, while LGNYZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas LGNYZ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to LGNYZ's ROE of -0.16%. Regarding short-term risk, NVACF is more volatile compared to LGNYZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check LGNYZ's competition here
NVACF vs AEGY Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, AEGY has a market cap of 411.2K. Regarding current trading prices, NVACF is priced at $1.26, while AEGY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas AEGY's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to AEGY's ROE of +0.00%. Regarding short-term risk, NVACF is more volatile compared to AEGY. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check AEGY's competition here
NVACF vs IPAH Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, IPAH has a market cap of 273.6K. Regarding current trading prices, NVACF is priced at $1.26, while IPAH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas IPAH's P/E ratio is -0.05. In terms of profitability, NVACF's ROE is +0.02%, compared to IPAH's ROE of -0.82%. Regarding short-term risk, NVACF is less volatile compared to IPAH. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check IPAH's competition here
NVACF vs SCRCQ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SCRCQ has a market cap of 141.1K. Regarding current trading prices, NVACF is priced at $1.26, while SCRCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SCRCQ's P/E ratio is -0.01. In terms of profitability, NVACF's ROE is +0.02%, compared to SCRCQ's ROE of +1.63%. Regarding short-term risk, NVACF is more volatile compared to SCRCQ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check SCRCQ's competition here
NVACF vs KIARF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, KIARF has a market cap of 132.6K. Regarding current trading prices, NVACF is priced at $1.26, while KIARF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas KIARF's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to KIARF's ROE of -1.47%. Regarding short-term risk, NVACF is less volatile compared to KIARF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check KIARF's competition here
NVACF vs FOGCF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, FOGCF has a market cap of 97.2K. Regarding current trading prices, NVACF is priced at $1.26, while FOGCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas FOGCF's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to FOGCF's ROE of +3.99%. Regarding short-term risk, NVACF is less volatile compared to FOGCF. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check FOGCF's competition here
NVACF vs MDIN Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, MDIN has a market cap of 90.3K. Regarding current trading prices, NVACF is priced at $1.26, while MDIN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas MDIN's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to MDIN's ROE of +0.36%. Regarding short-term risk, NVACF is more volatile compared to MDIN. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check MDIN's competition here
NVACF vs LGNDZ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, LGNDZ has a market cap of 73.3K. Regarding current trading prices, NVACF is priced at $1.26, while LGNDZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas LGNDZ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to LGNDZ's ROE of -0.16%. Regarding short-term risk, NVACF is more volatile compared to LGNDZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check LGNDZ's competition here
NVACF vs OXIHF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, OXIHF has a market cap of 65.7K. Regarding current trading prices, NVACF is priced at $1.26, while OXIHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas OXIHF's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to OXIHF's ROE of +3.30%. Regarding short-term risk, NVACF is more volatile compared to OXIHF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check OXIHF's competition here
NVACF vs IMMB Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, IMMB has a market cap of 57.5K. Regarding current trading prices, NVACF is priced at $1.26, while IMMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas IMMB's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to IMMB's ROE of -0.09%. Regarding short-term risk, NVACF is more volatile compared to IMMB. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check IMMB's competition here
NVACF vs AXMP Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, AXMP has a market cap of 40.9K. Regarding current trading prices, NVACF is priced at $1.26, while AXMP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas AXMP's P/E ratio is 0.05. In terms of profitability, NVACF's ROE is +0.02%, compared to AXMP's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to AXMP. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check AXMP's competition here
NVACF vs LGNXZ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, LGNXZ has a market cap of 40.5K. Regarding current trading prices, NVACF is priced at $1.26, while LGNXZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas LGNXZ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to LGNXZ's ROE of -0.16%. Regarding short-term risk, NVACF is more volatile compared to LGNXZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check LGNXZ's competition here
NVACF vs DECN Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, DECN has a market cap of 35.5K. Regarding current trading prices, NVACF is priced at $1.26, while DECN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas DECN's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to DECN's ROE of +0.00%. Regarding short-term risk, NVACF is more volatile compared to DECN. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check DECN's competition here
NVACF vs HADV Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, HADV has a market cap of 32.2K. Regarding current trading prices, NVACF is priced at $1.26, while HADV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas HADV's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to HADV's ROE of +0.83%. Regarding short-term risk, NVACF is more volatile compared to HADV. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check HADV's competition here
NVACF vs SPPH Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SPPH has a market cap of 29.4K. Regarding current trading prices, NVACF is priced at $1.26, while SPPH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SPPH's P/E ratio is -0.03. In terms of profitability, NVACF's ROE is +0.02%, compared to SPPH's ROE of -0.50%. Regarding short-term risk, NVACF is more volatile compared to SPPH. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check SPPH's competition here
NVACF vs WPHM Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, WPHM has a market cap of 23.2K. Regarding current trading prices, NVACF is priced at $1.26, while WPHM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas WPHM's P/E ratio is -0.01. In terms of profitability, NVACF's ROE is +0.02%, compared to WPHM's ROE of -1.56%. Regarding short-term risk, NVACF is more volatile compared to WPHM. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check WPHM's competition here
NVACF vs CAFS Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, CAFS has a market cap of 19.9K. Regarding current trading prices, NVACF is priced at $1.26, while CAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas CAFS's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to CAFS's ROE of +1.94%. Regarding short-term risk, NVACF is more volatile compared to CAFS. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check CAFS's competition here
NVACF vs TSTS Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, TSTS has a market cap of 12.8K. Regarding current trading prices, NVACF is priced at $1.26, while TSTS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas TSTS's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to TSTS's ROE of +2.32%. Regarding short-term risk, NVACF is less volatile compared to TSTS. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check TSTS's competition here
NVACF vs IXSBF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, IXSBF has a market cap of 12.6K. Regarding current trading prices, NVACF is priced at $1.26, while IXSBF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas IXSBF's P/E ratio is -0.01. In terms of profitability, NVACF's ROE is +0.02%, compared to IXSBF's ROE of +1.90%. Regarding short-term risk, NVACF is more volatile compared to IXSBF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check IXSBF's competition here
NVACF vs ALST Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ALST has a market cap of 10.8K. Regarding current trading prices, NVACF is priced at $1.26, while ALST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ALST's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to ALST's ROE of +0.13%. Regarding short-term risk, NVACF is more volatile compared to ALST. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check ALST's competition here
NVACF vs VIAP Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, VIAP has a market cap of 10.3K. Regarding current trading prices, NVACF is priced at $1.26, while VIAP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas VIAP's P/E ratio is -0.05. In terms of profitability, NVACF's ROE is +0.02%, compared to VIAP's ROE of +0.65%. Regarding short-term risk, NVACF is more volatile compared to VIAP. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check VIAP's competition here
NVACF vs OMHE Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, OMHE has a market cap of 9.8K. Regarding current trading prices, NVACF is priced at $1.26, while OMHE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas OMHE's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to OMHE's ROE of +0.73%. Regarding short-term risk, NVACF is more volatile compared to OMHE. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check OMHE's competition here
NVACF vs HBOSF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, HBOSF has a market cap of 7.8K. Regarding current trading prices, NVACF is priced at $1.26, while HBOSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas HBOSF's P/E ratio is 0.03. In terms of profitability, NVACF's ROE is +0.02%, compared to HBOSF's ROE of +6.69%. Regarding short-term risk, NVACF is more volatile compared to HBOSF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check HBOSF's competition here
NVACF vs PXYN Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, PXYN has a market cap of 6.3K. Regarding current trading prices, NVACF is priced at $1.26, while PXYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas PXYN's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to PXYN's ROE of -0.20%. Regarding short-term risk, NVACF is less volatile compared to PXYN. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check PXYN's competition here
NVACF vs IYXI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, IYXI has a market cap of 5.3K. Regarding current trading prices, NVACF is priced at $1.26, while IYXI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas IYXI's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to IYXI's ROE of +1.71%. Regarding short-term risk, NVACF is more volatile compared to IYXI. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check IYXI's competition here
NVACF vs RBII Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, RBII has a market cap of 5K. Regarding current trading prices, NVACF is priced at $1.26, while RBII trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas RBII's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to RBII's ROE of -0.04%. Regarding short-term risk, NVACF is more volatile compared to RBII. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check RBII's competition here
NVACF vs NEWG Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, NEWG has a market cap of 2.3K. Regarding current trading prices, NVACF is priced at $1.26, while NEWG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas NEWG's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to NEWG's ROE of +0.40%. Regarding short-term risk, NVACF is more volatile compared to NEWG. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check NEWG's competition here
NVACF vs FSPM Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, FSPM has a market cap of 1.3K. Regarding current trading prices, NVACF is priced at $1.26, while FSPM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas FSPM's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to FSPM's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to FSPM. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check FSPM's competition here
NVACF vs GRPI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, GRPI has a market cap of 1K. Regarding current trading prices, NVACF is priced at $1.26, while GRPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas GRPI's P/E ratio is -0.02. In terms of profitability, NVACF's ROE is +0.02%, compared to GRPI's ROE of +0.09%. Regarding short-term risk, NVACF is more volatile compared to GRPI. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check GRPI's competition here
NVACF vs ACGJ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ACGJ has a market cap of 324. Regarding current trading prices, NVACF is priced at $1.26, while ACGJ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ACGJ's P/E ratio is -0.00. In terms of profitability, NVACF's ROE is +0.02%, compared to ACGJ's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to ACGJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check ACGJ's competition here
NVACF vs MDVLQ Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, MDVLQ has a market cap of 161. Regarding current trading prices, NVACF is priced at $1.26, while MDVLQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas MDVLQ's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to MDVLQ's ROE of -2.39%. Regarding short-term risk, NVACF is more volatile compared to MDVLQ. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check MDVLQ's competition here
NVACF vs ISHI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, ISHI has a market cap of 5. Regarding current trading prices, NVACF is priced at $1.26, while ISHI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas ISHI's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to ISHI's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to ISHI. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check ISHI's competition here
NVACF vs SYNI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, SYNI has a market cap of 3. Regarding current trading prices, NVACF is priced at $1.26, while SYNI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas SYNI's P/E ratio is -0.00. In terms of profitability, NVACF's ROE is +0.02%, compared to SYNI's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to SYNI. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check SYNI's competition here
NVACF vs GHTI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, GHTI has a market cap of 0. Regarding current trading prices, NVACF is priced at $1.26, while GHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas GHTI's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to GHTI's ROE of N/A. Regarding short-term risk, NVACF is less volatile compared to GHTI. This indicates potentially lower risk in terms of short-term price fluctuations for NVACF.Check GHTI's competition here
NVACF vs TFSHF Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, TFSHF has a market cap of 0. Regarding current trading prices, NVACF is priced at $1.26, while TFSHF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas TFSHF's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to TFSHF's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to TFSHF. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check TFSHF's competition here
NVACF vs MDSI Comparison July 2025
NVACF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVACF stands at 78.5M. In comparison, MDSI has a market cap of 0. Regarding current trading prices, NVACF is priced at $1.26, while MDSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVACF currently has a P/E ratio of 31.60, whereas MDSI's P/E ratio is N/A. In terms of profitability, NVACF's ROE is +0.02%, compared to MDSI's ROE of N/A. Regarding short-term risk, NVACF is more volatile compared to MDSI. This indicates potentially higher risk in terms of short-term price fluctuations for NVACF.Check MDSI's competition here